ArticleFrontiers in immunology2025
Elucidating AML ribosome biogenesis reshaping prognostic assessment and immune microenvironment integrated single-cell and bulk RNA analysis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ribosome biogenesis and selective translational control as oncogenic vulnerabilities in hematologic malignancies.Molecular cancer · 2026Review
- Global bibliometric analysis of TP53-mutated acute myeloid leukemia: research hotspots and evolution.Translational cancer research · 2026Article
- Integrative single-cell and bulk transcriptomics define polyamine-associated cell states in acute myeloid leukemia and implicate CCT6A in polyamine homeostasis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy with significant clinical challenges due to its heterogeneity and high relapse rate. Dysregulated ribosome biogenesis is a recognized driver of tumorigenesis and therapy resistance, but its comprehensive impact on AML prognosis and the immune microenvironment remains to be fully elucidated. Methods: We constructed an AML single-cell atlas and quantified ribosome biogenesis activity. A prognostic ribosome biogenesis signature (RBS) was developed through integrated machine learning and interpreted using the SHapley Additive exPlanations (SHAP) framework. We evaluated the RBS associations with prognosis, tumor immune microenvironment, immunotherapy response, and drug sensitivity. Key findings were validated by qPCR, Western blot, and molecular docking. Results: Single-cell analysis revealed significantly elevated ribosome biogenesis activity scores (RAS, a composite metric quantifying cellular ribosome synthesis capacity) in AML stem and progenitor cells. The RBS model, established using a Random Survival Forest algorithm, demonstrated robust prognostic power. SHAP interpretation identified EXOSC2 as the top predictor. Low-RBS patients displayed an immune-activated microenvironment and heightened immunotherapy response. Molecular docking indicated high-affinity binding of ouabain and digoxin to EXOSC2. Conclusion: Our study delineates the critical role of ribosome biogenesis in AML progression and establishes an interpretable RBS prognostic signature. This tool effectively assesses immunotherapy responsiveness and reveals novel targeting opportunities, providing valuable insights for clinical decision-making to improve AML outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.